NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet ...
Boehringer Ingelheim has reported new phase 3 data showing its dual glucagon/GLP‑1 agonist survodutide achieved weight loss of up to 13.1% in adults with obesity and type 2 diabetes. The SYNCHRONIZE‑2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results